You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
港股异动 | 四环医药(0460.HK)涨超8% 轩竹生物新药XZP-5955片获批临床试验
格隆汇 06-03 10:34
格隆汇6月3日丨四环医药(0460.HK)高开高走,现报3.9港元,涨8.64%,暂成交2亿港元,最新市值369亿港元。四环医药今日早间公布,公司附属公司轩竹生物科技有限公司自主研发的1类新药XZP-5955片于2021年5月31日获得药物临床试验批准通知书,成为集团2021年1月继XZP-5610获得临床试验批准后又一个获批开展临床试验的创新药物。四环医药昨日午间亦公布,该集团将于中国地区独家代理引进韩国东方医疗株式会社(韩国东方医疗会社)旗下的爱拉丝提面部埋植线(线雕)和私密用线两类产品。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account